BioSpace News Archive

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 5:00pm ET (2:00pm PT). A webcast of the presentation will be posted under the investor relations section of Aurora Spine’s website at www.aurora-spine.com , or can be accessed at https://www.

KemPharm, Inc., a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2020 Annual Meeting of Stockholders to be held on June 19, 2020.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the expansion of

Kristin Dietzler has been appointed President of Carestream Health’s Americas Region, effective immediately.

The Maryland-based urgent care company has performed 11,000 COVID-19 tests and is now beginning to see an increase in non-COVID medical concerns

- Top-line results from a Phase 3 study evaluating RINVOQ in moderate to severe atopic dermatitis in adults and adolescents show both doses of upadacitinib (15 mg and 30 mg) monotherapy met all primary and secondary endpoints versus placebo[1] - No new safety risks were observed compared to the safety profile observed in patients with rheumatoid arthritis and psoriatic arthritis receiving RINVOQ[1-5] - RINVOQ, a selective and reversible JAK inhibitor discovered and developed

Catalyst Biosciences, Inc., announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, offered at a price of $6.50 per share to the public.

Almirall LLC today announced that the FDA approved an important update to the Seysara® label stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline

Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A

The gift is part of a $2.5 million SPIE education-funding initiative for optics and photonics